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Abstract
Background: Hepatitis B virus (HBV) genotypes have distinct geographic distribution. Moreover,
much genetic variability has been described in the precore (PC) and basal core promoter (BCP)
regions of the HBV genome. The local prevalence of HBV genotypes and mutations has not been
well studied. The aim of the present study is to determine the prevalence of HBV genotypes and
mutations in the PC and BCP region in HBV strains in Karachi.
Methods: A total of 109 chronic hepatitis B patients with detectable HBV DNA by a PCR assay
were enrolled in the study. Sera were tested for HBeAg, anti-HBe antibody and liver profile. HBV
genotypes and mutations in the PC and BCP regions were detected by INNO-LiPA line-probe
assays.
Results: Of the 109 patients investigated, 38 (35%) were HBeAg positive while 71 (65%) were
HBeAg negative. Genotype D was present in 100% of the patients. Two patients had co-infection
with genotype A. There was no significant difference in the baseline characteristics, mean ALT
levels, and presence of clinical cirrhosis in patients with HBeAg positive or negative strains with or
without PC and BCP mutations. Of the 38 HBeAg positive patients, 9 (24%) had PC and BCP
mutations. In the HBeAg negative patient group, mutations were detected in 44 (62%) of the strains
investigated. More than one mutation was common, seen in 26 (37%) patients with HBeAg negative
disease and 6 (16%) patients with HBeAg positive disease. Twelve (17%) HBeAg negative patients
had dual T1762 and A1764 mutations. None of the HBeAg positive patients had T1762 mutation.
Mutations were undetectable in 27 (38%) of patients with HBeAg negative disease.
Conclusion: Our study shows that type D is the main HBV genotype in Karachi, Pakistan.
Significant numbers of patients infected with this genotype have PC and BCP variants. Mutations at
more than one site are common. Patients harboring these mutants do not differ significantly in their
clinical presentation from patients having wild type infection.
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Background
Hepatitis B Virus (HBV) is a well-known agent of acute
and chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma. Around 400 million people worldwide carry
the virus of which more than 250 million reside in Asia
[1].
HBV has been classified into eight genotypes (A-H)
according to the criterion of = 8% differences in the com-
plete nucleotide sequence of the viral genome [2-5]. These
genotypes show variation in their geographic distribution
[4,6-8]. In addition to the epidemiological importance,
these genotypes may influence the disease pattern and
response to treatment.
In the natural course of chronic HBV infection, the loss of
HBeAg expression and the appearance of antibodies
directed against it (Anti-HBe) are usually accompanied by
cessation of viral replication. However such a serology
profile may also be seen in individuals who harbor pre-
core (PC) and basal core promoter (BCP) mutants where
replicative infection continues. The frequent genomic
mutation that leads to HBeAg negativity is the mutation of
the nucleotide (nt) 1896 from G to A (G-A). This muta-
tion converts codon 28 of the precore sequence to a termi-
nation codon (TGG→TAG) and thus prevents HBeAg
from being expressed [9]. PC variants are more common
among patients with genotype D (65 to 75 percent) than
genotype A (9 to 18 percent) [10,11].
A second group of mutations affect the basal core pro-
moter region and result in a transcriptional reduction of
precore but not pregenomic and core mRNA [12]. These
HBeAg suppressive strains contain mutations of nt1762
from A to T (A 1762 T) and nt 1764 from G to A (G 1764
A) in the BCP region and are the predominant quasispe-
cies in chronic hepatitis patients [13-16]. These mutations
may be found in isolation or in conjunction with PC
mutations. Occurrence of these mutations result in
increase in viral load [12,13,17,18]. These changes were
initially thought to be related to a "HBeAg-negative phe-
notype" but recent studies showed that they may also be
found in some HBeAg-positive patients, especially those
with chronic hepatitis [14,19].
The present study aimed to determine the HBV genotypes
in Karachi and the pattern of PC and BCP mutations. This
is the first study reporting the details of the PC and BCP
mutants from Pakistan.
Methods
Included in this study were 109 patients who visited the
liver clinic of our institute for further evaluation and ful-
filled the following criteria (1) HBsAg positive for more
than six months (2) HBV DNA positive (3)No other con-
comitant liver diseases including hepatitis C and HIV
infections, autoimmune hepatitis, Wilson's disease, pri-
mary biliary cirrhosis, alcoholic liver disease and non-
alcoholic fatty liver disease (4) No previous treatment for
hepatitis B. Demographic and clinical data of these
patients was recorded. Ethics Review Committee of the
hospital (SIUT) approved the protocol (see Additional file
1).
Informed consent was taken from patients fulfilling the
inclusion criteria and blood samples taken. They were
tested for alanine aminotransferase (ALT), alkaline phos-
phatase (ALP), serum albumin, bilirubin. Hepatitis B
serological markers were tested by micro-ELISA method
(AxSYM, Abbott laboratories, North Chicago, IL USA).
HBV DNA was extracted from 200 μl of serum using
QIAamp DNA Blood Mini Kit (Qiagen GmbH, Germany)
and amplified by an in-house PCR assay with a detection
limit of 1000 geq./ml. The primers used were P7 (5'-GTG
GTG GAC TTC TCT CAA TTT TC-3' nt. 256–278) and S1–
2 (5'-CGA ACC ACT GAA CAA ATG GC-3' nt. 685–704
[20].
HBV DNA positive samples were analyzed for viral geno-
types and mutations in the PC and BCP regions. We used
commercially available Line Probe Assays for HBV geno-
typing and mutation analysis (INNOGENETICS, Bel-
gium) [11,21,22]. INNO-LiPA PreCore kit detects
mutations in PC codon 28, and BCP nt 1762 and nt 1764.
The kit can detect a wild type/mutant mixed population of
circulating virus in contrast to sequencing which would
only identify the predominant variant.
The patients were labeled suffering from clinical cirrhosis
on the basis of clinical and ultrasound findings suggestive
of cirrhosis (nodular surface, firm consistency, blunt liver
edge, altered echotexure, dilated portal vein and splenom-
egaly) and evidence of hypersplenism (platelets < 100,00/
mm3).
Statistical analysis
The corrected chi-square test was used to compare categor-
ical data. Student t test or one-way analysis of variance was
used for group comparisons of parametric quantitative
data and the Mann-Whitney test for similar comparisons
of nonparametric data. In all cases, tests of significance
were two-tailed, with a level at less than 0.05. Results are
presented as median (range) or mean ± SD, whenever
appropriate. Statistical analysis was done with the statisti-
cal package SPSS for Windows 2000 (version 10.1, SPSS,
Chicago, IL).
Results
Our study population included 109 HBV DNA positive
chronic hepatitis B patients. The mean age of theseBMC Gastroenterology 2006, 6:20 http://www.biomedcentral.com/1471-230X/6/20
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patients was 32.6 ± 11.9 years (range 7–70 years). Eighty
five (78%) patients were male. Thirty eight patients (35%)
were HBeAg positive and 71 (65%) HBeAg negative. All
the HbeAg negative patients and one HBeAg positive
patients had Anti-HBe antibody positive. All of the sam-
ples belonged to genotype D except two patients who
were coinfected with genotype A. Characteristics of these
patients are given in Table 1. There was no difference in
terms of sex, age, biochemical profile and clinical cirrhosis
in HBeAg positive and negative variants.
Mutations in the PC and BCP regions were detected in 9
(24%) of HBeAg positive patients and 44 (62%) of HBeAg
negative patients (p = 000). Remaining patients had the
wild type band for both PC and BCP regions in the line
probe assay. BCP mutations were found in 45 (41%)
patients; 8 (21%) in HbeAg positive and 37 (52%) in
HBeAg negative group. PC mutations were found in 7
(18%) and 22 (31%) of HbeAg positive and negative
patients. Details of individual mutations are given in
Table 2. More than one mutation was common, seen in
26 (37%) patients with HBeAg negative disease and 6
(16%) patients with HBeAg positive disease. Twelve
(17%) HBeAg negative patients had dual T1762 and
A1764 mutations. None of the HBeAg positive patients
had T1762 mutation. Mutations were undetectable in 27
(38%) of patients with HBeAg negative disease.
The patients with wild type virus were younger than the
patients having mutant type virus in HBeAg negative
group (age 27.8 ± 9.6 vs 38.3 ± 12.9, p = 0.012). There
were no statistical differences in the laboratory parameters
and presence of clinical cirrhosis in patients harboring the
wild virus compared to the mutant variant in both HBeAg
negative and positive groups. Patients with normal ALT at
the time of presentation did not differ from patients with
elevated ALT in the frequency of different mutations.
Discussion
All of our patients had genotype D with two patients coin-
fected with type A. This pattern is unique when compared
to those of other countries in Asia. In South East Asia, gen-
otypes B and C are highly prevalent [23] and in India a
mixed pattern of genotypes D, A and C is seen [24,25].
There are therapeutic implications of this finding as
patients with genotype D have more severe disease [26]
and are less responsive to interferon therapy as compared
to genotype A and B [27,28] and have higher HBV DNA
levels (8). Moreover, in this genotype, specific viral
sequence patterns present before initiation of therapy
appear to be predictive of long-term response to lamivu-
dine treatment [29].
The incidence of HBeAg negative chronic hepatitis B has
increased in many countries [30]. In our study HBeAg neg-
ative patients predominated. This does not represent the
true prevalence of the HBeAg negative disease as the sam-
ples were collected by convenience sampling. However, it
does signify its high prevalence. Information about preva-
lence of PC and BCP mutations is also important in terms
of response to interferon, development of fulminant hep-
atitis, rate of lamivudine resistant mutants and develop-
ment of hepatocellular carcinoma [31]. Studies have
shown that the PC variant is more prevalent among
Table 1: Characteristics of patients, HBV genotypes and mutant
HBeAg Negative Patients (n = 
71)
HBeAg Positive Patients (n = 
38)
p value
Sex (M/F) 57/14 28/10 0.428
Age (Yrs) 33.8 ± 12.6 31.4 ± 11.5 0.464
Serum bilirubin (mg/dl) 1.4 ± 2.9 0.9 ± 0.8 0.247
ALT (U/L) 61 ± 79 93 ± 137 0.236
Alkaline phosphatase (U/L) 169 ± 124 195 ± 169 0.450
Serum Albumin (g/dl) 3.5 ± 1.0 3.6 ± 1.1 0.714
Platelet count (106/μL) 179 ± 76 171 ± 80 0.751
Clinical cirrhosis 16 06 0.717
Genotype D* 71 38 1.000
Coinfection with genotype 00 02
Mutations
Precore G1896A 22 07 0.157
BCP A1762T 11 00 0.010√
BCP G1764A 27 06 0.016√
Absent wild PC band 22 05 0.040√
Absent wild BCP band 34 07 0.002√
Overall mutants** 44 09 0.000√
More than one mutations 26 06 0.023√
*Genotype D present in all the patients. **More than one mutations in many patients. PC: precore, BCP: basal core promoter. √Significant p valuesBMC Gastroenterology 2006, 6:20 http://www.biomedcentral.com/1471-230X/6/20
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patients with genotype D, the type found in our patients,
than in type A [10,11]. This mutation (G1896A) stabilizes
the epsilon structure in the PC gene by forming a base pair
with nt 1858 which exists as T in this genotype [32]. Treat-
ing these patients with interferon results in high relapse
rates [33,34].
62% of our HBeAg negative patients and 24% of HBeAg
positive patients had PC and BCP mutants (p = 000) so
the frequency was more in those who did not express
HBeAg. Combining HBeAg positive and negative groups
PC variants were present in 29 (27%) and BCP variants in
44 (40%) patients. There was an overlap with mutations
present at more than one site. There are some reports of
association of PC mutation with fulminant hepatic failure
[35] and the BCP variants with more severe liver damage
[36-39] and HCC [40-43]. Other workers could not con-
firm a specific mutation predicting fulminant disease
[44]. BCP mutations may not be necessarily pathogenic as
they have been found in acute self limiting hepatitis,
chronic hepatitis and asymptomatic carriers [45]. In our
study, ALT levels and prevalence of clinical cirrhosis did
not differ significantly in patients without or with PC or
BCP mutants in both HBeAg negative and positive sub-
groups. Clinical relevance of these variants may be over-
stated and any correlation of nucleotide sequences with
clinical and serologic findings must be done with precau-
tion [46].
Studies from Asia suggested that the dual core promoter
variant (A1762T, G1764A) was more common in patients
with genotype C than those with genotype B [37,47].
Double mutation may enhance viral replication [13]. In
our study most of the patients had HBV mutations at
more than one sites. Twelve (17%) HBeAg negative
patients had dual T1762 and A1764 mutations. None of
the HBeAg positive patients had T1762 mutation.
In some of our patients though the line probe assay could
not detect a specific mutation at 1762, 1764, and 1896
position but the wild PC or BCP band was absent. The
samples were retested and the control bands worked in
each run. This raises the possibility of other mutations in
these regions undetected by INNO-LiPA (Table 2). It
would be worthwhile investigating further these patients
as it has been shown that three other nucleotide muta-
tions at position 1817, 1874, 1897 also cause truncation
in HBeAg and other changes that affect initiation codon at
1814, 1815 and 1816 have also been reported [48]. More-
over certain deletion mutations will not be detected by
INNO-LiPA. Bozdayi et al [49] showed the existence of
considerable variability between nucleotides 1751–1775
of the core promoter region in genotype D. Twenty seven
(38%) of our HBeAg negative patients did not show any
mutation by the assay we used.
Twenty four percent of our HBeAg positive patients had
PC and BCP mutations. HBeAg did not disappear even in
the presence of PC mutation. It may be due to presence of
a mixed infection with the mutant and wild type viruses.
Presence of wild type virus is needed by some of the
mutants such as deletion mutants within the core pro-
moter and core gene as well as variants with large dele-
tions for infection of hepatocytes as shown for the
Table 2: Details of precore (PC) and basal core promotor (BCP) mutations as detected by line probe assays for PC 1896, BCP 1762, 
BCP 1764 and wild PC and BCP regions (n = 53)
HBeAg Negative Patients (n = 44) n
PC (1896) alone 03
BCP 1762 alone 01
BCP 1764 alone 08
PC + 1764 06
BCP 1762 + 1764 03
PC + 1762 + 1764 06
PC + presence of wild PC band 02
PC + BCP 1762 + BCP 1764 + presence of wild PC band 02
Absent wild BCP band alone* 04
Absent PC wild band* 02
PC + absent wild BCP band 02
Miscellaneous combinations 05
HBeAg Positive Patients (n = 9)
BCP 1764 + PC 04
BCP 1764 alone 01
Absent wild BCP band alone* 01
Miscellaneous combinations 03
PC = precore, BCP = basal core promoter
*Wild band and specified mutation bands absent. Thus mutations not detected by LiPABMC Gastroenterology 2006, 6:20 http://www.biomedcentral.com/1471-230X/6/20
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woodchuck hepatitis virus [50]. It appears that HBV exists
as a quasi species of wild type and mutant clones even in
the HBeAg positive phase [46]. Direct sequencing can not
detect a mutant population unless it accounts for a major-
ity of the total population while INNO-LiPA assay is able
to pick up the mixed infection.
Davidson F, et al compared the line probe assay we used
with direct sequence analysis and found it more sensitive
in detecting mixed infection. PC and BCP mutants were
detected in three-fourth (74%) of patients with genotype
D [51]. These mutations were picked up in half (49%) of
cases in our study. In a study done by sequence analysis of
Turkish patients with genotype D, BCP mutations were
found in 17% and 29% of HbeAg positive and negative
patient [49]. Our data suggests the figure of 21% and
52%. Perhaps geographical differences, host factors and
type of assay used may influence the outcome.
Conclusion
In conclusion, genotype D is the main HBV genotype in
Karachi, Pakistan and significant number of our patients
have PC and BCP variants. Patients harboring these
mutants do not differ significantly in their clinical presen-
tation from patients having wild type infection.
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